Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Date:12/9/2008

com/prereg/key.process?key=PKCEC99FG.

To access the live conference call via phone, dial 888-713-4214. International callers may access the live call by dialing 617-213-4866. The reference number to enter the call is 61907318.

The replay of the conference call may be accessed via the Internet, at http://www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 85181265.

About Acute Agitation

Acute agitation affects many people suffering from major psychiatric disorders, including schizophrenia and bipolar disorder. Patients experiencing agitation become uncomfortable, tense, and restless, and as the agitation intensifies, patients can become threatening and violent if the agitation is not treated.

Based on the Company's analysis of patient information from the National Institute of Mental Health (NIMH), the company believes that in the United States schizophrenia afflicts about 2.5 million adults and bipolar disorder affects about 6 million adults. The Company believes approximately 90% of these patients experience agitation at some point during their lifetime, and more than two-thirds of this group will suffer at least one episode -- and often up to six episodes -- of agitation every year, with about half of the cases requiring hospitalization.

Agitation is currently treated with injectable and oral anti-psychotic medications: the oral medications work relatively slowly and while the intramuscular injections have a faster onset of action, they are invasive and can be frightening to patients. The American Association of Emergency Psychiatrists published the Expert Consensus Guidelines for the Treatment of Behavioral Emergencies in 2001, which state three key treatment attributes for choosing treatment f
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
2. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... BOSTON, Jan. 27, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... the three months ended December 31, 2010 in the amount ... a result of instrument sales to over fifty Hospitals, Clinics, ... States. Solos looks towards continued growth in 2011 ...
... /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. ... the "Company"), a leading developer, manufacturer and marketer of ... and other health and nutritional products in the People,s ... products, Ranitidine Hydrochloride Capsule, has been added to the ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 3
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have ... (COPD) who are also depressed have difficulty sticking ... be particularly true for women, and screening and ... part of treatment. The study and its findings ... . , Chronic obstructive pulmonary disease is ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... In this season of giving and sharing, St.,David,s Community ... $5.15 million in grants to area nonprofit organizations that ... "Especially this year, we ... care for Central Texans," said Earl Maxwell, CEO of ...
... Dec. 16 Globus Medical, Inc., the largest privately ... the appointment of Wendy DiCicco, CPA, as Chief Financial ... of a publicly traded medical device manufacturer to the ... she was the CFO for Kensey Nash Corporation (Nasdaq: ...
... 16 SunTrust Banks, Inc.,(NYSE: STI ... for employers seeking to take control of their ... administrative and financial,components, including a healthcare payment card, ... options, offered,through a single trusted custodial partner. , ...
... January 2009 issue, The Journal of Nuclear Medicine ... , "This change to the publication allows the ... structure and organization of research reports," said Heinrich R. ... of Nuclear Medicine . "Most important and critical, it ...
... The Body By Milk campaign -- famous for,putting white ... up with the,five-time GRAMMY(R)-Award winning and multi-platinum selling artist, Usher, ... the Body By,Milk got noise? music video program. , ... give 20 lucky teens the chance to flex their,creative muscle ...
... 16 December 2008 - The effectiveness of voriconazole in ... study to be featured in the International Journal ... Elsevier. Fungal infections can kill people with weakened immune ... or organ replacement, and the research reinforces earlier findings ...
Cached Medicine News:Health News:$5.15 Million Provided to Support Local Health Care Needs 2Health News:$5.15 Million Provided to Support Local Health Care Needs 3Health News:$5.15 Million Provided to Support Local Health Care Needs 4Health News:Globus Medical Strengthens Executive Team with Appointment of CFO 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 3Health News:Journal of Nuclear Medicine premiers new, full-color design 2Health News:Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity 2Health News:Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity 3Health News:Voriconazole: A highly potent treatment for fungal infections 2
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: